$155.7 M

ADMA Mkt cap, 18-Jan-2019

$4.2 M

ADMA Biologics Revenue Q3, 2018
ADMA Biologics Net income (Q3, 2018)-15.1 M
ADMA Biologics EBIT (Q3, 2018)-13.8 M
ADMA Biologics Cash, 30-Sep-201842.4 M
ADMA Biologics EV139.5 M

ADMA Biologics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3.1m5.9m7.2m10.7m22.8m

Revenue growth, %

93%21%49%

R&D expense

9.3m7.0m7.7m6.2m

General and administrative expense

4.4m6.7m8.5m18.1m

Operating expense total

18.1m22.7m28.0m62.1m

Depreciation and amortization

1.2m

EBIT

(15.0m)(16.0m)(15.5m)(17.3m)(39.3m)

EBIT margin, %

(490%)(271%)(216%)(163%)(173%)

Interest expense

618.2k1.3m1.8m2.2m3.3m

Interest income

7.6k14.2k37.8k50.3k57.2k

Pre tax profit

(15.5m)(17.4m)(18.0m)

Net Income

(15.5m)(16.8m)(18.0m)(19.5m)(43.8m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.1m1.6m1.5m1.4m1.5m1.3m1.9m2.1m2.3m2.9m2.6m3.4m4.7m4.0m4.7m4.2m

R&D expense

1.4m4.3m1.8m1.5m1.4m1.5m2.1m2.0m3.4m1.7m1.2m1.4m1.8m1.3m1.5m1.3m

General and administrative expense

845.3k1.1m1.5m1.0m1.3m1.4m2.1m1.7m1.7m1.8m4.3m4.4m4.2m5.0m5.0m5.4m

Operating expense total

3.6m7.2m5.1m4.4m4.7m4.8m6.5m6.3m7.8m6.7m8.6m11.8m19.2m20.6m18.1m18.0m

Depreciation and amortization

73.0k273.8k211.2k211.2k211.2k

EBIT

(2.5m)(5.7m)(3.6m)(3.0m)(3.2m)(3.5m)(4.7m)(4.2m)(5.5m)(3.7m)(5.9m)(8.4m)(14.4m)(16.5m)(13.4m)(13.8m)

EBIT margin, %

(229%)(364%)(239%)(222%)(213%)(268%)(252%)(196%)(242%)(127%)(226%)(247%)(305%)(409%)(288%)(326%)

Interest expense

162.9k226.9k342.8k335.3k476.0k453.4k449.3k467.4k538.0k606.0k618.5k642.5k783.0k1.3m1.4m1.4m

Interest income

2.1k1.8k3.6k3.5k5.0k9.8k11.1k13.5k12.0k11.6k18.6k7.9k8.0k26.5k33.1k75.6k

Pre tax profit

(2.7m)

Net Income

(2.7m)(5.9m)(4.0m)(3.4m)(3.6m)(4.7m)(5.1m)(4.6m)(6.0m)(4.3m)(6.5m)(9.0m)(15.2m)(17.8m)(14.7m)(15.1m)

ADMA Biologics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.1m17.2m10.4m9.9m43.1m

Accounts Receivable

384.0k924.5k1.0m3.9m

Inventories

1.7m1.7m3.4m5.0m12.6m

Current Assets

31.1m24.1m21.3m21.7m63.2m

PP&E

30.5m

Goodwill

3.5m

Total Assets

32.0m27.2m23.7m23.7m108.0m

Accounts Payable

2.7m1.8m2.1m2.6m5.9m

Short-term debt

6.1m

Current Liabilities

3.7m4.2m4.2m11.2m9.4m

Long-term debt

25.4m

Total Debt

6.1m25.4m

Total Liabilities

10.4m22.9m28.1m67.7m

Common Stock

3.7k

Additional Paid-in Capital

74.2m75.5m88.2m102.5m191.0m

Retained Earnings

(52.6m)(69.4m)(87.4m)(106.9m)(150.7m)

Total Equity

21.6m6.0m821.0k40.3m

Debt to Assets Ratio

0.3 x

Financial Leverage

1.5 x4.5 x28.9 x2.7 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

5.4m26.5m17.9m14.0m16.6m7.8m9.2m8.9m12.5m7.9m8.5m25.6m13.6m26.1m55.2m42.4m

Accounts Receivable

335.1k484.4k803.5k562.2k351.4k522.5k1.2m944.0k826.7k1.3m839.9k2.3m1.5m3.7m3.8m4.1m

Inventories

1.2m984.5k1.1m1.5m1.9m2.5m2.8m4.0m4.2m4.6m5.3m13.2m13.4m12.4m12.2m13.9m

Current Assets

7.1m30.8m26.5m22.6m31.0m27.1m25.2m17.4m29.5m25.4m15.7m44.3m31.4m46.4m73.6m62.5m

PP&E

28.6m29.8m30.6m30.3m30.4m

Goodwill

3.5m3.5m3.5m3.5m3.5m

Total Assets

8.7m32.0m27.9m25.3m33.9m29.8m27.8m19.7m31.7m27.5m17.6m84.6m72.8m91.1m117.8m106.3m

Accounts Payable

1.5m2.8m2.3m2.4m1.8m1.6m2.2m2.5m3.3m2.8m3.9m4.7m9.2m5.7m3.1m5.3m

Short-term debt

4.4m6.7m6.7m

Current Liabilities

2.5m4.3m3.8m4.1m3.8m3.2m4.3m4.3m5.1m9.2m13.0m15.6m13.3m9.4m6.9m9.9m

Long-term debt

9.4m14.5m25.6m25.9m26.2m

Total Debt

4.4m6.7m16.0m14.5m25.6m25.9m26.2m

Total Liabilities

9.4m16.0m15.6m16.0m20.5m20.3m22.9m23.1m27.8m27.6m28.4m57.0m59.8m68.1m66.0m69.1m

Additional Paid-in Capital

47.2m74.4m74.8m75.1m86.5m87.3m87.8m88.7m102.0m102.2m102.7m150.2m150.7m191.5m235.0m235.6m

Retained Earnings

(47.9m)(58.5m)(62.5m)(65.9m)(73.1m)(77.7m)(82.8m)(92.0m)(98.0m)(102.4m)(113.5m)(122.5m)(137.7m)(168.5m)(183.3m)(198.4m)

Total Equity

15.9m12.3m9.2m13.4m9.5m4.9m3.9m(10.8m)27.7m13.0m23.0m51.8m37.2m

Debt to Equity Ratio

-0.6 x0.6 x1.1 x0.5 x0.7 x

Debt to Assets Ratio

0.2 x0.4 x0.2 x0.2 x0.2 x0.2 x

Financial Leverage

2 x2.3 x2.7 x2.5 x3.1 x5.7 x8.1 x-1.6 x3.1 x5.6 x4 x2.3 x2.9 x

ADMA Biologics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(15.5m)(16.8m)(18.0m)(19.5m)(43.8m)

Depreciation and Amortization

210.6k247.9k469.8k469.6k2.7m

Accounts Receivable

39.1k(384.0k)(540.5k)(93.6k)(2.9m)

Inventories

(403.5k)(39.7k)(1.7m)(1.6m)589.3k

Accounts Payable

1.6m(937.8k)308.7k476.8k2.8m

Cash From Operating Activities

(10.9m)(14.7m)(15.4m)(18.3m)(37.3m)

Purchases of PP&E

(196.6k)(2.3m)(26.1k)(73.4k)(2.7m)

Cash From Investing Activities

(3.1m)(4.0m)(1.7m)904.6k15.2m

Cash From Financing Activities

27.6m9.8m10.4m16.8m60.8m

Interest Paid

382.7k785.5k1.3m1.5m

ADMA Biologics Ratios

USDY, 2018

EV/EBIT

-10.1 x

EV/CFO

-3.2 x

Debt/Equity

0.7 x

Debt/Assets

0.2 x

Financial Leverage

2.9 x
Report incorrect company information

ADMA Biologics Employee Rating

1.04 votes
Culture & Values
1.0
Work/Life Balance
2.2
Senior Management
1.2
Salary & Benefits
1.5
Career Opportunities
1.0
Source